Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

44.25USD
26 Nov 2014
Price Change (% chg)

$0.09 (+0.20%)
Prev Close
$44.16
Open
$44.30
Day's High
$44.41
Day's Low
$43.99
Volume
978,525
Avg. Vol
1,363,224
52-wk High
$44.77
52-wk Low
$35.65

ABT.N

Chart for ABT.N

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of healthcare products. The Company’s business segments include established pharmaceutical products, which include gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products,... (more)

Overall

Beta: 0.61
Market Cap (Mil.): $66,631.23
Shares Outstanding (Mil.): 1,505.79
Dividend: 0.22
Yield (%): 1.99

Financials

  ABT.N Industry Sector
P/E (TTM): 40.54 37.83 38.74
EPS (TTM): 1.09 -- --
ROI: 5.22 17.93 17.27
ROE: 7.21 18.73 18.18
Search Stocks

Factbox: Another U.S. tax 'inversion' implodes, pending deals dwindle

- Another proposed U.S. corporate tax "inversion" deal collapsed on Friday when Irish food group Fyffes Plc and larger U.S. rival Chiquita Brands International Inc called off an agreement to combine.

24 Oct 2014

Abbott, Mylan silent on why changing tax-inversion terms

- Drugmakers Abbott Laboratories and Mylan Inc on Wednesday declined to explain in detail why they changed the terms of a $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and reincorporate for tax purposes in the Netherlands.

22 Oct 2014

UPDATE 2-Abbott, Mylan silent on why changing tax-inversion terms

(Adds analyst, banker comments, companies declining explanations)

22 Oct 2014

Abbott, Mylan back generics deal, tweak terms after tax rule change

Oct 22 - Abbott Laboratories and Mylan Inc on Wednesday said they would go ahead with their $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and set up headquarters in the Netherlands, but they tweaked the terms of the transaction.

22 Oct 2014

Abbott says third-quarter sales match forecasts

- Abbott Laboratories said its third-quarter sales were in line with Wall Street forecasts and that it had slightly changed the terms of a deal to sell generic drugs to Mylan Inc .

22 Oct 2014

Abbott, AbbVie win dismissal of claims over Humira, AndroGel

- A federal judge in Chicago dismissed racketeering claims in a lawsuit accusing Abbott Laboratories and AbbVie Inc of causing health plans to pay unnecessarily for the latter's blockbuster Humira arthritis drug and AndroGel testosterone drug instead of cheaper generics.

25 Sep 2014

Abbott, AbbVie win dismissal of claims over Humira, AndroGel

Sept 25 - A federal judge in Chicago dismissed racketeering claims in a lawsuit accusing Abbott Laboratories and AbbVie Inc of causing health plans to pay unnecessarily for the latter's blockbuster Humira arthritis drug and AndroGel testosterone drug instead of cheaper generics.

25 Sep 2014

Abbott dissolving stent has lower angina rate vs metal stent: study

- Abbott's Absorb dissolving heart stent proved as safe and effective one year after being placed in a diseased artery as the company's market-leading Xience drug coated metal stent with a significantly lower rate of chest pain, according to data presented at a medical meeting on Sunday.

14 Sep 2014

Abbott dissolving stent has lower angina rate vs metal stent -study

Sept 14 - Abbott's Absorb dissolving heart stent proved as safe and effective one year after being placed in a diseased artery as the company's market-leading Xience drug coated metal stent with a significantly lower rate of chest pain, according to data presented at a medical meeting on Sunday.

14 Sep 2014

Fitch Maintains CFR's IDRs on Rating Watch Positive

(The following statement was released by the rating agency) CHICAGO, August 29 (Fitch) Fitch Ratings maintains CFR Pharmaceuticals S.A. and its subsidiary CFR International SpA on Rating Watch Positive in anticipation of their acquisition by Abbott Investments Luxembourg S.A.R.L., a subsidiary of Abbott Laboratories (Abbott; rated 'A+' by Fitch). A complete list of rating actions follows at the end of this press release. KEY RATING DRIVERS Rating Watch Positive Fitch initially placed the co

29 Aug 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $107.21 +0.51
Pfizer Inc. (PFE.N) $31.10 +0.63
Novartis AG (NOVN.VX) CHF93.00 --
Merck & Co., Inc. (MRK.N) $59.75 +0.41
Sanofi SA (SASY.PA) €77.42 +0.19
AstraZeneca plc (AZN.L) 4,735.00p +14.50
GlaxoSmithKline plc (GSK.L) 1,483.50p +5.00
Eli Lilly and Co (LLY.N) $67.32 +0.47
Amgen, Inc. (AMGN.OQ) $164.72 --
Medtronic, Inc. (MDT.N) $73.48 +0.69

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks